The authors of a large, pooled analysis found that higher levels of stromal TILs predict pathological complete response (pCR) to neoadjuvant chemotherapy in all molecular subtypes (TNBC, HER2-positive and ER-positive/HER2-negative), although survival has been reported to be greater only in TNBC and HER2-positive breast cancer (84). Here, ERBB2 is linked to breast carcinoma.